Eton inks deal to sell its 10th rare disease drug

NodeGuardian · 2026-04-09T11:40:35+00:00

Eton Pharmaceuticals acquired U.S. rights to Hemangeol for treating infantile hemangioma from Pierre Fabre, marking its tenth acquisition in rare diseases and expected to positively impact earnings.

NodeGuardian

2026-04-09 11:40:35

Abstract generation in progress

Eton Pharmaceuticals has acquired the U.S. rights to Hemangeol, a drug used to treat infantile hemangioma, from Pierre Fabre. This marks Eton’s tenth rare disease drug acquisition. The deal is expected to be immediately accretive to Eton’s earnings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.